The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst
: Sir, on the U.S. business, we've seen a Q-o-Q sharpish decline in the business. Can you help us understand the drivers in terms of what sort of led
-- because what our understanding was that there is seasonality in our business and sort of largest one-off on sales in the Q4 U.S. sales. And [clinging]
to that, how should we look at U.S. sales progression through the quarters now for the year?
Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst
: Okay. And then secondly, in terms of -- on your emerging market business, the biologics approvals and all that you talked about, the impact of
that, will it be visible, start getting visible to this year? Or it's going to be more like a FY '22 onwards opportunity?
Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst
: And sir, how many biologics have we -- are we looking at on average across these major geographies to come through? And secondly is the fact
that we will be not filing them -- these biologics in U.S. or not looking to get any approval right now, is there a hindrance in getting approvals to
this geography?
Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst
: So will you be able to name some of these -- [key] of the important or largest biosimilars you're looking at?
Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst
: My questions have been answered. Thank you.
without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.
AUGUST 05, 2020 / 10:30AM, CADI.NS - Q1 2021 Cadila Healthcare Ltd Earnings Call
| 
